3662 Federal Register / Vol. 89, No. 13 / Friday, January 19, 2024 / Notices 

Rule requirements and the basis for the 

calculations summarized below, see 88 

FR 59923. 

Your comment—including your name 

and your state—will be placed on the 

public record of this proceeding. 

Because your comment will be made 

public, you are solely responsible for 

making sure that your comment does 

not include any sensitive personal 

information, such as anyone’s Social 

Security number; date of birth; driver’s 

license number or other state 

identification number or foreign country 

equivalent; passport number; financial 

account number; or credit or debit card 

number. You are also solely responsible 

for ensuring that your comment does 

not include any sensitive health 

information, such as medical records or 

other individually identifiable health 

information. In addition, your comment 

should not include any ‘‘[t]rade secret or 

any commercial or financial information 

which is . . . privileged or 

confidential’’—as provided in Section 

6(f) of the FTC Act 15 U.S.C. 46(f), and 

FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)— 

including, in particular, competitively 

sensitive information, such as costs, 

sales statistics, inventories, formulas, 

patterns devices, manufacturing 

processes, or customer names. 

Josephine Liu, 

Assistant General Counsel for Legal Counsel. 

[FR Doc. 2024–01004 Filed 1–18–24; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

[Docket No. ATSDR–2023–0005] 

Availability of Two Draft Toxicological 

Profiles 

AGENCY: Agency for Toxic Substances 

and Disease Registry (ATSDR), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Agency for Toxic 

Substances and Disease Registry 

(ATSDR), within the Department of 

Health and Human Services (HHS), 

announces the opening of a docket to 

obtain comments on drafts of two 

updated toxicological profiles: 

chloroform and chloroethane. This 

action is necessary as this is the 

opportunity for members of the public 

and organizations to submit comments 

on drafts of the profiles. The intended 

effect of this action is to ensure that the 

public can note any pertinent additional 

information or reports on studies about 

the health effects caused by exposure to 

the substances covered in these two 

profiles for review. 

DATES: Written comments must be 

received on or before April 18, 2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. ATSDR–2023– 

0005 by either of the methods listed 

below. Do not submit comments by 

email. ATSDR does not accept 

comments by email. 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Agency for Toxic Substances 

and Disease Registry, Office of 

Innovation and Analytics, 4770 Buford 

Highway, Mail Stop S106–5, Atlanta, 

GA 30341–3717. Attn: Docket No. 

ATSDR–2023–0005. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to http://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

http://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Farhana Rahman, Agency for Toxic 

Substances and Disease Registry, Office 

of Innovation and Analytics, 4770 

Buford Highway, Mail Stop S106–5, 

Atlanta, GA 30329–4027; Email: 

ATSDRToxProfileFRNs@cdc.gov; Phone: 

1–800–232–4636. 

SUPPLEMENTARY INFORMATION: ATSDR 

has prepared drafts of two updated 

toxicological profiles based on current 

understanding of the health effects and 

availability of new studies and other 

information since their initial release. 

All toxicological profiles issued as 

‘‘Drafts for Public Comment’’ represent 

the result of ATSDR’s evidence-based 

evaluations of the available literature to 

provide important toxicological 

information on priority hazardous 

substances to the public and health 

professionals. ATSDR considers key 

studies for these substances during the 

profile development process, using a 

systematic review approach. To that 

end, ATSDR is seeking public 

comments and additional information or 

reports on studies about the health 

effects of these substances for review 

and potential inclusion in the profiles. 

ATSDR will evaluate the quality and 

relevance of such data or studies for 

possible inclusion in the profile. 

Legislative Background 

The Superfund Amendments and 

Reauthorization Act of 1986 (SARA) [42 

U.S.C. 9601 et seq.] amended the 

Comprehensive Environmental 

Response, Compensation, and Liability 

Act of 1980 (CERCLA or Superfund) [42 

U.S.C. 9601 et seq.] by establishing 

certain requirements for ATSDR and the 

U.S. Environmental Protection Agency 

(EPA) regarding the hazardous 

substances most commonly found at 

facilities on the CERCLA National 

Priorities List. Among these statutory 

requirements is a mandate for the 

Administrator of ATSDR to prepare 

toxicological profiles for each substance 

included on the priority list of 

hazardous substances [also called the 

Substance Priority List (SPL)]. This list 

identifies 275 hazardous substances that 

ATSDR has determined pose the most 

significant potential threat to human 

health. The SPL is available online at 

http://www.atsdr.cdc.gov/SPL. ATSDR 

is also mandated to revise and publish 

updated toxicological profiles, as 

necessary, to reflect updated health 

effects and other information. 

In addition, CERCLA provides ATSDR 

with the authority to prepare 

toxicological profiles for substances not 

found on the SPL. CERCLA authorizes 

ATSDR to establish and maintain an 

inventory of literature, research, and 

studies on the health effects of toxic 

substances (CERCLA Section 

104(i)(1)(B); 42 U.S.C. 9604(i)(1)(B)); to 

respond to requests for health 

consultations (CERCLA Section 

104(i)(4); 42 U.S.C. 9604(i)(4)); and to 

support the site-specific response 

actions conducted by the agency 

(CERCLA Section 104(i)(6); 42 U.S.C. 

9604(i)(6)). 

ATSDR has now prepared drafts of 

two updated toxicological profiles based 

on current understanding of the health 

effects and availability of new studies 

and other information since their initial 

release. 

Availability 

The draft toxicological profiles and 

interaction profile are available online 

at http://www.regulations.gov, Docket 

No. ATSDR–2023–0005 and at http://

www.atsdr.cdc.gov/ToxProfiles. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 13 / Friday, January 19, 2024 / Notices 3663 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

ATSDR will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. Do not submit comments by 

email. ATSDR does not accept 

comments by email. 

Donata Green, 

Associate Director, Office of Policy, Planning 

and Partnerships, Agency for Toxic 

Substances and Disease Registry. 

[FR Doc. 2024–01007 Filed 1–18–24; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2024–0003] 

Meeting of the Advisory Committee to 

the Director, Centers for Disease 

Control and Prevention 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting for the Advisory 

Committee to the Director, Centers for 

Disease Control and Prevention (ACD, 

CDC). This is a hybrid meeting, 

accessible both in person and virtually 

(webcast live via the World Wide Web). 

It is open to the public and limited only 

by the space available. Time will be 

available for public comment. 

DATES: The meeting will be held on 

February 21, 2024, from 9 a.m. to 3 p.m., 

EST (times subject to change). 

Written comments must be received 

on or before February 5, 2024. 

ADDRESSES: Meeting address: CDC 

Roybal Campus, Building 21, Room 

1204 A/B, 1600 Clifton Road NE, 

Atlanta, Georgia 30329–4027. 

Please note that the meeting location, 

the CDC Roybal Campus, is a federal 

facility and in-person access is limited 

to United States citizens unless prior 

authorizations, taking up to 30 to 60 

days, have been made. Visitors must 

follow all directions for access to CDC 

facilities. Directions for visitors to CDC, 

including safety requirements related to 

COVID–19; are available at https://

www.cdc.gov/screening/visitors.html. 

Registration: You must register to 

attend this meeting in person. If you 

wish to attend in person, please submit 

a request by email to ACDirector@

cdc.gov at least 5 business days in 

advance of the meeting. No registration 

is required to view the meeting via the 

World Wide Web. Information for 

accessing the webcast will be available 

at https://www.cdc.gov/about/advisorycommittee-director/. 

Written comments: You may submit 

comments, identified by Docket No. 

CDC–2024–0003, by either of the 

following methods below. Do not 

submit comments for the docket by 

email. CDC does not accept comments 

for the docket by email. 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Kerry Caudwell, DPA, Centers 

for Disease Control and Prevention, 

1600 Clifton Road NE, Mailstop H21–10, 

Atlanta, Georgia 30329–4027. Attn: 

Docket number CDC–2024–0003. 

Instructions: All submissions received 

must include the Agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to https://www.regulations.gov, 

including any personal information 

provided. For access to the docket to 

read background documents or 

comments received, go to https://

www.regulations.gov. Written comments 

received in advance of the meeting will 

be included in the official record of the 

meeting. 

FOR FURTHER INFORMATION CONTACT: 

Kerry Caudwell, D.P.A., Office of the 

Chief of Staff, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H21–10, Atlanta, 

Georgia 30329–4027, Telephone: (404) 

639–0390; Email Address: ACDirector@

cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Advisory Committee to 

the Director, CDC, shall (1) make 

recommendations to the Director 

regarding ways to prioritize the 

activities of the agency in alignment 

with the CDC Strategic Plan required 

under section 305(c); H.R. 2617–1252; 

(2) advise on ways to achieve or 

improve performance metrics in relation 

to the CDC Strategic Plan, and other 

relevant metrics, as appropriate; (3) 

provide advice and recommendations 

on the development of the Strategic 

Plan, and any subsequent updates, as 

appropriate; (4) advise on grant, 

cooperative agreements, contracts, or 

other transactions, as applicable; (5) 

provide other advice to the Director, as 

requested, to fulfill duties under 

sections 301 and 311; and (6) appoint 

subcommittees. The committee 

recommends ways to prioritize CDC’s 

activities, improve results, and address 

health disparities. It also provides 

guidance to help CDC work more 

effectively with its various private and 

public sector constituents to make 

health protection a practical reality. 

Matters to be Considered: The agenda 

includes updates on CDC programs, 

Director’s focus areas, and the Moving 

Forward Initiative. Agenda items are 

subject to change as priorities dictate. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: The docket 

will be opened to receive written 

comments on January 19, 2024 through 

February 5, 2024. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 


ddrumheller on DSK120RN23PROD with NOTICES1